The burgeoning landscape of medication for obesity and type 2 glucose intolerance is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant differences in their pharmacological profiles and clinical study results are emerging. Retatrutide,… Read More

Arriving in the landscape of obesity management, retatrutide presents a different method. Unlike many current medications, retatrutide operates as a dual agonist, simultaneously engaging both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) receptors. The simultaneous stimulation promotes several helpful effects, includin… Read More